ABCC2 and squamous cell carcinoma: Silencing ANRIL can suppress cell proliferation, promote cell apoptosis, and reduce the expression of drug transporter MRP1 and ABCC2, thus enhancing the cisplatin-sensitivity of oral squamous cell carcinoma cells [33].